Binds Lymphokine, Cytokine, Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator Specific For A Hematopoietic Cell (e.g., Interleukin, Interferon, Erythropoietin, Etc.) Patents (Class 530/388.23)
-
Patent number: 7405274Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.Type: GrantFiled: June 1, 2004Date of Patent: July 29, 2008Assignee: FibroGen, Inc.Inventors: Al Y. Lin, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang, David A. Yeowell
-
Patent number: 7402662Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.Type: GrantFiled: March 13, 2006Date of Patent: July 22, 2008Assignee: UCB Pharma S.A.Inventors: Dilijeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
-
Patent number: 7396911Abstract: This invention provides a chimeric DNA molecule comprising a sequence encoding a chemokine polypeptide covalently attached to a heterologous polypeptide, the encoded chimeric polypeptide, and uses thereof.Type: GrantFiled: July 7, 2003Date of Patent: July 8, 2008Assignee: Genetics Institute, LLCInventors: Stephen H. Herrmann, Stephen L. Swanberg
-
Publication number: 20080160030Abstract: The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFN?”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, 1, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFN? protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFN? subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFN? related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.Type: ApplicationFiled: February 9, 2006Publication date: July 3, 2008Inventors: Jacques F. Banchereau, Kiley Prilliman, Virginia Pascual, Anna Karolina Palucka
-
Patent number: 7390491Abstract: Midkine (MK), which is a retinoic acid-inducible heparin-binding growth factor, enhances neutrophilic migration and exists in an inflammatory state at a high concentration. The midkine or its inhibitors can be used for treating neutrophilic functional disorders or inflammatory diseases.Type: GrantFiled: November 18, 2002Date of Patent: June 24, 2008Assignee: Takashi MuramatsuInventors: Tohru Takada, Kazuhiro Toriyama, Hisako Muramatsu, Takashi Muramatsu
-
Patent number: 7390490Abstract: There are provided uses of an antibody directed to CX3CR1 and fractalkine. Killer lymphocytes can be readily identified, eliminated and separated by using an anti-CX3CR1 antibody. Further, there can be provided an antibody drug for suppressing chemotaxis and cytotoxic activity of killer lymphocytes by suppressing an interaction between CX3CR1 and fractalkine.Type: GrantFiled: September 13, 2005Date of Patent: June 24, 2008Assignee: Eisai Co., Ltd.Inventors: Toshio Imai, Miyuki Nishimura, Kenzo Muramoto, Yoshikazu Kuboi
-
Patent number: 7387776Abstract: Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: January 7, 2003Date of Patent: June 17, 2008Assignee: Medarex, Inc.Inventors: Tibor Keler, Robert Graziano, John Treml, Yashwant M. Deo
-
Publication number: 20080138349Abstract: The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds an Fc?R that activates a cellular effector (“Fc?RActivating,” such as Fc?RIIA or Fc?RIIIA) and an Fc?R that inhibits a cellular effector (“Fc?RInhibiting,” such as Fc?RIIA) with an altered Ratio of Affinities relative to the respective binding affinities of such Fc?R for the Fc region of the wild-type immunoglobulin. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by Fc?R is desired (e.g.Type: ApplicationFiled: December 7, 2007Publication date: June 12, 2008Applicant: Macrogenics, Inc.Inventors: Jeffrey B. Stavenhagen, Scott Koenig
-
Patent number: 7381801Abstract: Chimeric antibodies, as well as fusion proteins which comprise chimeric antibodies, are disclosed. The antibodies bind to GM-CSF, CD-30, and G250 antigen. The fusion proteins include biologically active portions of tumor necrosis factor, or full length tumor necrosis factor. Expression vectors adapted for production of the antibodies, as well as methods for manufacturing these, are also disclosed.Type: GrantFiled: February 12, 2003Date of Patent: June 3, 2008Assignee: Ludwig Institute for Cancer ResearchInventors: Christoph Renner, Antony Burgess, Andrew Scott
-
Publication number: 20080118517Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: June 27, 2007Publication date: May 22, 2008Applicants: MEDAREX, INC., GENMAB A/SInventors: Jessica Teeling, Paul Parren, Ole Baadsgaard, Debra Hudson, Jorgen Petersen
-
Patent number: 7374761Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: August 8, 2007Date of Patent: May 20, 2008Assignees: Centocor, Inc., New York UniversityInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7371825Abstract: The present invention relates to at least one novel anti-MCP-1 antibodies, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: June 29, 2005Date of Patent: May 13, 2008Assignee: Centocor, Inc.Inventors: Anuk Das, Jill M. Carton
-
Patent number: 7371377Abstract: The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.Type: GrantFiled: June 19, 2002Date of Patent: May 13, 2008Assignee: Genentech, Inc.Inventors: Napoleone Ferrara, Sophia S. Kuo
-
Patent number: 7371383Abstract: The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.Type: GrantFiled: April 11, 2003Date of Patent: May 13, 2008Assignees: MedImmune, Inc., Ludwig Institute for Cancer ResearchInventors: Jennifer Lynne Reed, William Dall'Acqua, Jacques Van Snick, Jean-Christophe Renauld, Francoise Cormont, Catherine Uyttenhove
-
Patent number: 7371826Abstract: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.Type: GrantFiled: May 8, 2006Date of Patent: May 13, 2008Assignee: Genentech, Inc.Inventor: Leonard Presta
-
Patent number: 7368111Abstract: Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGF?) bind specifically isoforms TGF?2 and TGF?1 or both, preferentially compared with TGF?3. Specific binding members may be isolated and utilized in the treatment of disease, particularly fibrotic disease and also immune/inflammatory diseases. Therapeutic utility is demonstrated using in vitro and in vivo models. Full sequence and binding information is provided, including epitope sequence information for particularly advantageous specific binding member which binds the active form of TGF?2, neutralizing its activity, but does not bind the latent member.Type: GrantFiled: July 23, 2003Date of Patent: May 6, 2008Assignees: Cambridge Antibody Technology Limited, Medical Research CouncilInventors: Julia Elizabeth Thompson, Tristan John Vaughan, Andrew James Williams, Jonathan Alexander Green, Ronald Henry Jackson, Louise Bacon, Kevin Stuart Johnson, Alison Jane Wilton, Philip Ronald Tempest, Raymond Paul Field, Steven Paul Ruddock, Gregory Paul Winter
-
Patent number: 7364865Abstract: There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine ?8 (CK?8 or ckb-8)); a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1-? and chemokine ?1(CK?1 or ckb-1)), and a macrophage inhibitory protein-4 (MIP-4), as well as MPIF-1, M-CIF and/or MIP-4 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same.Type: GrantFiled: May 5, 2006Date of Patent: April 29, 2008Assignee: Human Genome Sciences, Inc.Inventors: Reiner L. Gentz, Brent L. Kreider, Jun Zhang, Michael Antonaccio, Donna Mendrick, Pablo Jimenez, Vikram Patel, Craig A. Rosen, Mark D. Adams, Haodong Li, Steven M. Ruben
-
Patent number: 7361474Abstract: The present invention provides methods for detecting, diagnosing or prognosticating prostate cancer by measuring the levels of macrophage migration inhibitory factor (MIF) in the serum of an individual. The assay for MIF can be an immunoassay, such as ELISA, or a nucleic assay, such as Nouthern blot. Genetic changes within MIF gene can predict patients that express high levels of MIF.Type: GrantFiled: December 17, 2003Date of Patent: April 22, 2008Assignee: United States of America as represented by The Department of Veterans AffairsInventor: Katherine Meyer Siegler
-
Patent number: 7354584Abstract: The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.Type: GrantFiled: April 12, 2004Date of Patent: April 8, 2008Assignee: MedImmune, Inc.Inventors: Jennifer Lynne Reed, Herren Wu, Ying Tang, Julian Davies, Jeffry D. Watkins
-
Patent number: 7355014Abstract: A human IFN-? inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel INF-? inducing polypeptide or active fragments thereof are formulated and monoclonal antibodies are raised against this polypeptide or antigenic fragments thereof. The polypeptide can be used in a method for treating diseases susceptive to treatment with INF-?, and methods for enhancing the cytotoxicity of NK cells or for inducing the formation of LAK cells, such as to treat tumors and malignant pathologies.Type: GrantFiled: October 16, 2006Date of Patent: April 8, 2008Assignee: Kabushiki Kaisha Hay Ashibara Seibutsu Kagaku KenkyujoInventors: Shimpei Ushio, Kakuji Torigoe, Todao Tanimoto, Haruki Okamura, Masashi Kurimoto, Shigeharu Fukuda, Toshio Kunikata, Mutsuko Taniguchi, Keizo Kohno
-
Patent number: 7342110Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.Type: GrantFiled: April 10, 2006Date of Patent: March 11, 2008Assignee: Immunogen Inc.Inventors: Mary G. Hoffee, Daniel Tavares, Robert J. Lutz
-
Patent number: 7335358Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: December 4, 2006Date of Patent: February 26, 2008Assignees: Centocor, Inc., New York UniversityInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Publication number: 20080038254Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.Type: ApplicationFiled: August 11, 2006Publication date: February 14, 2008Applicant: Biogen Idec Inc.Inventors: Darrell R. Anderson, Nabil Hanna, Peter Brams
-
Patent number: 7329737Abstract: The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.Type: GrantFiled: August 3, 2005Date of Patent: February 12, 2008Assignee: Dyax Corp.Inventors: Daniel J. Sexton, Andrew Nixon, Anthony Williams, Robert C. Ladner, Qi-Long Wu
-
Patent number: 7329405Abstract: Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: February 26, 2003Date of Patent: February 12, 2008Assignee: Genmab A/SInventors: Jan G. J. van de Winkel, Marcus A. van Dijk, Janine Schuurman, Arnout F. Gerritsen, Ole Baadsgaard, Jørgen Petersen
-
Patent number: 7317089Abstract: Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b(e.g., KD=10?8 M or less), a slow off rate for TNFSF13b dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize TNFSF13b activity in vitro and in vivo. The antibodies of the invention are useful in one embodiment for inhibiting TNFSF13b activity in a human subject suffering from a disorder in which hTNFSF13b activity is detrimental. Nucleic acids encoding the antibodies of the present invention, as well as, vectors and host cells for expressing them are also encompassed by the invention.Type: GrantFiled: August 15, 2002Date of Patent: January 8, 2008Assignee: Eli Lilly and CompanyInventor: Kristine Kay Kikly
-
Patent number: 7314722Abstract: The invention relates to cytostatin II growth modulatory polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.Type: GrantFiled: April 13, 2004Date of Patent: January 1, 2008Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Guo-Liang Yu, Reiner L. Gentz
-
Patent number: 7312320Abstract: This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.Type: GrantFiled: December 10, 2004Date of Patent: December 25, 2007Assignee: Novimmune SAInventor: Greg Elson
-
Patent number: 7307152Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: October 20, 2004Date of Patent: December 11, 2007Assignee: Genentech, Inc.Inventors: Luc Desnoyers, Napoleone Ferrara, Ellen Filvaroff, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
-
Patent number: 7300916Abstract: A pharmaceutical preparation for preventing and/or treating hypertrophic scars, keloid or chronic arthritic diseases comprising as an effective component an erythropoietin antagonist. More specifically, there is provided a pharmaceutical preparation for preventing and/or treating hypertrophic scars, keloid or chronic arthritic diseases comprising as an effective component an erythropoietin antagonist such as an anti-erythropoietin antibody, an erythropoietin receptor protein, etc. This pharmaceutical preparation has excellent prophylactic and/or therapeutic effects on collagenous hyperproliferation such as hypertrophic scars, keloid, etc., or chronic arthritic diseases such as rheumatoid arthritis, etc.Type: GrantFiled: February 26, 2002Date of Patent: November 27, 2007Inventors: Yoshiko Yasuda, Yukio Nakamura, Hitoshi Murakami, Koichi Ueda
-
Publication number: 20070264263Abstract: Disclosed are compositions and methods of treating a cytokine mediated diseases by inhibiting Sema7A and VLA-1 interaction.Type: ApplicationFiled: October 17, 2006Publication date: November 15, 2007Inventors: Hitoshi Kikutani, Atsushi Kumanogoh, Kenji Sugiyama
-
Patent number: 7288250Abstract: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.Type: GrantFiled: September 10, 2004Date of Patent: October 30, 2007Assignee: Critical Therapeutics, Inc.Inventors: Walter Newman, Shixin Qin, Theresa L. O'Keefe, Robert A. Obar
-
Patent number: 7285269Abstract: Antibodies directed to the antigen TNF? and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNF?. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.Type: GrantFiled: December 2, 2003Date of Patent: October 23, 2007Assignee: Amgen Fremont, Inc.Inventors: John S. Babcook, Jaspal S. Kang, Orit Foord, Larry Green, Xiao Feng, Scott Klakamp, Mary Haak-Frendscho, Palaniswami Rathanaswami, Craig Pigott, Meina Liang, Yen-Wah Lee, Kathy Manchulenko, Raffaella Faggioni, Giorgio Senaldi, Qiaojuan Jane Su
-
Patent number: 7285642Abstract: The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another mammal. The composition in particular modulates the interactions between a dendritic cell and a T-cell, more specifically between a C-type lectin on the surface of a dendritic cell and an ICAM receptor on the surface of a T-cell. The compositions can be used for preventing/inhibiting immune responses to specific antigens, for inducing tolerance, for immunotherapy, for immunosuppression, for the treatment of autoimmune diseases, and the treatment of allergy. The compound that binds to a C-type lectin is preferably chosen from mannose, fucose, plant lectins, antibiotics, sugars, proteins or antibodies against C-type lectins. The invention also relates to such antibodies.Type: GrantFiled: July 23, 2003Date of Patent: October 23, 2007Assignee: Katholieke Universiteit NijmegenInventors: Carl Gustav Figdor, Teunis Bernard Herman Geijtenbeek, Yvette Van Kooyk, Ruurd Torensma
-
Patent number: 7279559Abstract: Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.Type: GrantFiled: September 27, 2002Date of Patent: October 9, 2007Assignee: Genetics Institute, LLCInventors: Kenneth Jacobs, Debra D. Pittman, Lynette Fouser, Vikki Spaulding, Dejun Xuan
-
Patent number: 7276239Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: December 20, 2005Date of Patent: October 2, 2007Assignees: Centocor, Inc., New York UniversityInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7273609Abstract: The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF? inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF? inhibitors.Type: GrantFiled: August 18, 2006Date of Patent: September 25, 2007Assignee: Immunex CorporationInventors: Kendall M. Mohler, Dauphine S. Barone, Mary K. Kennedy
-
Patent number: 7270816Abstract: Nucleic acids encoding mammalian, e.g., primate, IL-1?, purified IL-1? polypeptides and fragments thereof. Binding proteins, e.g., antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.Type: GrantFiled: October 27, 2003Date of Patent: September 18, 2007Assignee: Schering CorporationInventor: Jacqueline C. Timans
-
Patent number: 7264801Abstract: The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Also provided herein are methods of screening for modulators of EG-VEGF. Furthermore, methods and related methods of treatment are described herein which pertain to regulating cellular proliferation and chemotaxis.Type: GrantFiled: December 19, 2001Date of Patent: September 4, 2007Assignee: Genentech, Inc.Inventors: Napoleone Ferrara, Colin Watanabe, William I. Wood, Theresa Shek
-
Patent number: 7265211Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.Type: GrantFiled: March 24, 2003Date of Patent: September 4, 2007Assignee: ZymoGenetics, Inc.Inventors: Wenfeng Xu, Wayne Kindsvogel, Steven D. Hughes, Yasmin A. Chandrasekher
-
Patent number: 7261893Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism.Type: GrantFiled: October 21, 2003Date of Patent: August 28, 2007Assignees: Wyeth, Cambridge Antibody Technology LimitedInventors: Geertruida M. Veldman, Monique V. Davies, Kening Song, Neil M. Wolfman, Kristie Grove Bridges, Anne Field, Caroline Russell, Viia Valge-Archer
-
Publication number: 20070190057Abstract: The present invention relates to methods of modulating (e.g., reducing) the mannose content, particularly high-mannose content of recombinant glycoproteins.Type: ApplicationFiled: December 22, 2006Publication date: August 16, 2007Inventors: Jian Wu, Nicole Le, Michael De La Cruz, Gregory Flynn
-
Patent number: 7252823Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: February 6, 2004Date of Patent: August 7, 2007Assignees: Centocor, Inc., New York UniversityInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7253265Abstract: An antibody and a method for producing an antibody that specifically binds to a full length amino acid sequence of human Delta-1.Type: GrantFiled: January 27, 2005Date of Patent: August 7, 2007Assignee: Asahi Kasei Kabushiki KaishaInventors: Seiji Sakano, Akira Itoh
-
Patent number: 7253264Abstract: The invention relates to genetically engineered soluble fusion proteins composed of human proteins not belonging to the immunoglobulin family, or of parts thereof, and of various portions of the constant region of immunoglobulin molecules. The functional properties of the two fusion partners are surprisingly retained in the fusion protein.Type: GrantFiled: August 22, 1994Date of Patent: August 7, 2007Assignees: Sanofi-Arentideutschland GmbH, The General Hospital CorporationInventors: Leander Lauffer, Gerd Zettlmeissl, Patricia Oquendo, Brian Seed
-
Patent number: 7250276Abstract: The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, the use of such polypeptides and fragmented peptides in cellular and immune reactions and as molecular weight markers, the use of such polypeptides and fragmented peptides as controls for peptide fragmentation, and kits comprising these reagents.Type: GrantFiled: November 12, 2004Date of Patent: July 31, 2007Assignee: Immunex CorporationInventors: John E Sims, Dirk E Smith
-
Patent number: 7250165Abstract: The present invention relates to at least one novel anti-TNF antibodies, including isolated nucleic acids that encode at least one anti-TNF antibody, TNF, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: August 1, 2001Date of Patent: July 31, 2007Assignee: Centocor, Inc.Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
-
Patent number: 7247711Abstract: Novel anti-IL-23p40 specific human Ig derived proteins, including, without limitation, antibodies, fusion proteins, and mimetibodies, isolated nucleic acids that encode the anti-IL-23p40 Ig derived proteins, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, are useful for therapeutic compositions, methods and devices. Preferably, the anti-IL-23p40 specific human Ig derived proteins do not bind the p40 subunit of IL-12 and, thus, do not neutralize IL-12-related activity.Type: GrantFiled: May 6, 2004Date of Patent: July 24, 2007Assignee: Centocor, Inc.Inventors: Jacqueline Benson, Mark Cunningham
-
Patent number: 7241576Abstract: The present invention is directed to the applications of a novel cytokine, named THANK, for TNF homologue that activates apoptosis, NF-?B and c-jun N-terminal kinase. Such applications include using THANK inhibitors to inhibit the activation of NF-?B and to treat a pathological condition caused by the activation of NF-?B. Also provided is a method of inhibiting growth of a wide variety of tumor cells by administering THANK protein.Type: GrantFiled: June 13, 2002Date of Patent: July 10, 2007Assignee: Research Development FoundationInventor: Bharat B. Aggarwal
-
Patent number: 7227003Abstract: Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, peptides, methods of making and using the antibody or peptides in immunoassays and immuno-therapeutic approaches are provided, where the anti-TNF peptide is selected from a soluble portion of TNF receptor, an anti-TNF antibody or structural analog thereof.Type: GrantFiled: June 2, 2005Date of Patent: June 5, 2007Assignees: New York University, Centocor, Inc.Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight, Scott A. Siegel